Published clinical validation of serum NfL (but not pNfH) as biomarker for ALS therapy development.

NfL has utility as both prognostic and potential pharmacodynamic biomarkers.

Used as a prognostic marker, NfL might yield modest sample size savings in phase II ALS trials.

Used as a pharmacodynamic marker, NfL could dramatically reduce sample size in phase II ALS trials.